SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease

Summary

Translumina has officially initiated the SPARX Global Randomized Controlled Trial to evaluate a drug-coated balloon-first strategy in complex coronary disease treatment. The multinational trial marks a significant step in advancing evidence for DCB therapy in this patient population.